Travere Therapeutics, Inc. (TVTX) intrinsic value & 10-year financials
Travere Therapeutics, Inc. (TVTX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 15.6% a year to $490.7M, with an average return on invested capital of -233.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $49.60
- Market cap
- $4.4B
- Revenue (FY2025)
- $490.7M
- Revenue growth (10-yr CAGR)
- 15.6%
- ROIC (10-yr avg)
- -233.1%
- Free cash flow (FY2025)
- —
TVTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $490.7M | -$25.5M | -$0.29 | — | -12.8% | -248.0% |
| FY2024 | $233.2M | -$321.5M | -$4.08 | — | -138.9% | -353.9% |
| FY2023 | $145.2M | -$111.4M | -$1.50 | -$280.7M | -267.2% | -446.3% |
| FY2022 | $212.0M | -$278.5M | -$4.37 | -$186.5M | -125.7% | -302.0% |
| FY2021 | $227.5M | -$180.1M | -$3.01 | -$19.9M | -71.1% | -100.3% |
| FY2020 | $198.3M | -$169.4M | -$3.56 | -$49.5M | -88.8% | -98.5% |
| FY2019 | $175.3M | -$146.4M | -$3.46 | -$58.4M | -78.3% | -82.7% |
| FY2018 | $164.2M | -$102.7M | -$2.54 | -$25.7M | -48.7% | — |
| FY2017 | $154.9M | -$59.7M | -$1.54 | $6.5M | -34.7% | — |
| FY2016 | $133.6M | -$47.9M | -$1.29 | -$4.9M | -43.6% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Travere Therapeutics, Inc. is a consistent compounder, expanding top-line revenue at 15.6% annually over the past decade.
Travere Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -42.1% ROIC.
Travere Therapeutics, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Travere Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-9.63 per share.